메뉴 건너뛰기




Volumn 26, Issue 1, 2010, Pages 79-85

Coverage with evidence development: Applications and issues

Author keywords

Coverage with Evidence Development; Economics; Evidence based healthcare; Insurance coverage

Indexed keywords

CRITICAL CHALLENGES; DATA COLLECTION; DEGREE OF UNCERTAINTY; HEALTH TECHNOLOGY ASSESSMENTS; HEALTH-CARE INSURANCE; MEDICAL LITERATURES; NEW TECHNOLOGIES; REAL-WORLD;

EID: 77949883892     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462309990882     Document Type: Review
Times cited : (62)

References (19)
  • 1
    • 77953589679 scopus 로고    scopus 로고
    • CCRE Therapeutics, (accessed February 16, 2009)
    • CCRE Therapeutics. Bosentan patient registry. 2005. http:// www.bosentanregistry.com.au/ (accessed February 16, 2009).
    • Bosentan Patient Registry 2005
  • 3
    • 77953582850 scopus 로고    scopus 로고
    • Conditional reimbursment based on future research
    • Chalkidou K. Conditional reimbursment based on future research. ISPOR Connect. 2008;14:9-10.
    • (2008) ISPOR Connect , vol.14 , pp. 9-10
    • Chalkidou, K.1
  • 4
    • 3042676609 scopus 로고    scopus 로고
    • Outcomes guarantee for lipid-lowering drugs: Results from a novel approach to risk sharing in primary care
    • Chapman S, Reeve E, Price D, Rajaratnam G, Neary R. Outcomes guarantee for lipid-lowering drugs: results from a novel approach to risk sharing in primary care. Br J Cardiol. 2004;11:205-210.
    • (2004) Br J Cardiol , vol.11 , pp. 205-210
    • Chapman, S.1    Reeve, E.2    Price, D.3    Rajaratnam, G.4    Neary, R.5
  • 5
    • 0032944813 scopus 로고    scopus 로고
    • Bayesian approaches to the value of information: Implications for the regulation of new pharmaceuticals
    • Claxton K. Bayesian approaches to the value of information: Implications for the regulation of new pharmaceuticals. Health Econ. 1999;8:269-274.
    • (1999) Health Econ , vol.8 , pp. 269-274
    • Claxton, K.1
  • 7
    • 33750600068 scopus 로고    scopus 로고
    • Using value of information analysis to prioritise health research: Some lessons from recent UK experience (Conference Paper)
    • Claxton K, SculpherMJ. Using value of information analysis to prioritise health research: Some lessons from recent UK experience (Conference Paper). Pharmacoeconomics. 2006;24:1055-1068.
    • (2006) Pharmacoeconomics , vol.24 , pp. 1055-1068
    • Claxton, K.1    Sculpher, M.J.2
  • 9
    • 33750587608 scopus 로고    scopus 로고
    • Building bridges between academic research and policy formulation: The PRUFE Framework-an Integral Part of Ontario's Evidence-Based HTPA Process
    • Goeree R, Levin L. Building bridges between academic research and policy formulation: The PRUFE Framework-an Integral Part of Ontario's Evidence-Based HTPA Process. Pharmacoeconomics. 2006;24:1143-1156.
    • (2006) Pharmacoeconomics , vol.24 , pp. 1143-1156
    • Goeree, R.1    Levin, L.2
  • 10
    • 35348858847 scopus 로고    scopus 로고
    • Coverage with evidence development: An examination of conceptual and policy issues
    • Hutton J, Trueman P, Henshall C. Coverage with evidence development: An examination of conceptual and policy issues. Int J Technol Assess Health Care. 2007;23:425-435.
    • (2007) Int J Technol Assess Health Care , vol.23 , pp. 425-435
    • Hutton, J.1    Trueman, P.2    Henshall, C.3
  • 13
    • 77953560942 scopus 로고    scopus 로고
    • (accessed October 20, 2008)
    • Multiple Sclerosis Resource Centre. Disease modifying drugs risk sharing scheme. 2002. http://www.msrc.co.uk/ index.cfm?fuseaction=show&pageid= 1893&CFID=8452005 &CFTOKEN=9967130 (accessed October 20, 2008).
    • (2002) Disease Modifying Drugs Risk Sharing Scheme
  • 14
    • 77953591723 scopus 로고    scopus 로고
    • (accessed February 5, 2009)
    • Tracleer-A cornerstone of oral therapy. 2007. http://www. tracleer.com/default.asp?page=HCP-AboutTracleer&kw= bosentan&gclid= CPP88t7K-5gCFQ9Jagodah6ToQ (accessed February 5, 2009).
    • (2007) Tracleer-A Cornerstone of Oral Therapy
  • 15
    • 34948904387 scopus 로고    scopus 로고
    • Effectiveness and safety of drug-eluting stents in Ontario
    • Tu JV, Bowen J, Chiu M, et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007;357:1393-1402.
    • (2007) N Engl J Med , vol.357 , pp. 1393-1402
    • Tu, J.V.1    Bowen, J.2    Chiu, M.3
  • 17
    • 33749332084 scopus 로고    scopus 로고
    • Coverage options for promising technologies: Medicare's 'Coverage with Evidence Development'
    • Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare's 'Coverage with Evidence Development'. Health Aff (Millwood). 2006;5:1218-1230.
    • (2006) Health Aff (Millwood) , vol.5 , pp. 1218-1230
    • Tunis, S.R.1    Pearson, S.D.2
  • 19
    • 33748347529 scopus 로고    scopus 로고
    • Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia
    • Wlodarczyk JH, Cleland LG, Keogh AM, et al. Public funding of bosentan for the treatment of pulmonary artery hypertension in Australia. Pharmacoeconomics. 2006;24:903-915.
    • (2006) Pharmacoeconomics , vol.24 , pp. 903-915
    • Wlodarczyk, J.H.1    Cleland, L.G.2    Keogh, A.M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.